esophagogastrectomy

PROCEDURE2 trials

Sponsors

Universitätsklinikum Hamburg-Eppendorf, Memorial Sloan Kettering Cancer Center

Conditions

Carcinomas of the Esophagogastric JunctionEsophageal AdenocarcinomaGastroesophageal Junction Adenocarcinoma

Phase 1

Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer

Active, not recruitingNCT02962063

Memorial Sloan Kettering Cancer CenterEsophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

Start: 2016-11-01End: 2026-11-01Updated: 2026-09-09

Unknown Phase

Esophagogastrectomy Versus Extended Gastrectomy in AEG II

CompletedNCT02302118

Universitätsklinikum Hamburg-EppendorfCarcinomas of the Esophagogastric Junction

Start: 2013-04-30End: 2015-11-30Updated: 2015-12-03

Related Papers

Survival outcomes for phase II study of durvalumab (D) and tremelimumab (T) plus PET-directed chemoradiation (CRT) in patients (Pts) with esophageal adenocarcinoma (EA).

Journal of Clinical Oncology2026-01-10

Phase 1b/II study of durvalumab (D) and tremelimumab (T) plus PET-adjudicated chemoradiation (CRT) in patients (Pts) with esophageal adenocarcinoma.

Journal of Clinical Oncology2024-01-201 citations

Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastrooesophageal carcinoma with dysphagia: a single arm phase II clinical trial (PALEO, sponsored by the Australasian Gastro-Intestinal Trials Group).

2022-12-173 citations

Durvalumab (D) and PET-directed chemoradiation (CRT) after induction FOLFOX for esophageal adenocarcinoma: Final results.

Journal of Clinical Oncology2022-06-016 citations

Durvalumab (D) and PET-directed chemoradiation (CRT) after induction FOLFOX for esophageal adenocarcinoma.

Journal of Clinical Oncology2021-01-206 citations

Durvalumab (D) and PET-directed chemoradiation (CRT) after induction FOLFOX for esophageal adenocarcinoma.

Journal of Clinical Oncology2020-02-01

Phase Ib/II trial of durvalumab and chemoradiation (CRT) with carboplatin/paclitaxel for esophageal and gastroesophageal junction (GEJ) adenocarcinoma.

Journal of Clinical Oncology2018-02-013 citations